Last reviewed · How we verify
Standard Triple
Standard Triple is a fixed-dose combination of three antiretroviral agents used to suppress HIV replication.
Standard Triple is a fixed-dose combination of three antiretroviral agents used to suppress HIV replication. Used for HIV-1 infection in treatment-naïve patients, HIV-1 infection in treatment-experienced patients (formulation-dependent).
At a glance
| Generic name | Standard Triple |
|---|---|
| Also known as | Standard Triple Therapy for H. pylori, Hp-PAC |
| Sponsor | University of Alberta |
| Drug class | Antiretroviral combination therapy |
| Target | HIV reverse transcriptase, HIV protease (depending on formulation) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Standard Triple typically combines two nucleoside reverse transcriptase inhibitors (NRTIs) with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI), working synergistically to block HIV replication at multiple steps. This combination approach reduces the likelihood of resistance development and improves virological suppression compared to monotherapy or dual therapy.
Approved indications
- HIV-1 infection in treatment-naïve patients
- HIV-1 infection in treatment-experienced patients (formulation-dependent)
Common side effects
- Nausea
- Diarrhea
- Headache
- Rash
- Lipodystrophy
- Hepatotoxicity
Key clinical trials
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer (PHASE2)
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (PHASE3)
- Tocilizumab in Lung Transplantation (PHASE2)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients (PHASE2)
- Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy (PHASE3)
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) (PHASE1, PHASE2)
- Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Triple CI brief — competitive landscape report
- Standard Triple updates RSS · CI watch RSS
- University of Alberta portfolio CI